Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Roche Gets Reprieve On Avastin For Breast Cancer With Delay At FDA

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA extends user fee date in lieu of reaching decision on whether or not to pull the breast cancer approval for bevacizumab.

You may also be interested in...



Roche Plays Up Potential First-In-Class Schizophrenia Drug In R&D Review

Roche has launched an expansive Phase III program for the glycine reuptake inhibitor RG1678 for both positive and negative symptoms of the disease.

Roche Plays Up Potential First-In-Class Schizophrenia Drug In R&D Review

Roche has launched an expansive Phase III program for the glycine reuptake inhibitor RG1678 for both positive and negative symptoms of the disease.

FDA Official Stresses "Flexibility" On Speeding Approval Of Drugs That Truly Stand Out

Four-year study of cancer drugs shows tyrosine kinase inhibitors commonly get cleared based on Phase II data in both accelerated and regular approvals. Emerging new classes could find faster paths.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS071193

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel